Company / SG&A Expense
Actinium Pharmaceuticals, Inc. SG&A Expense History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$15.2M
FY2025
5-year range
$6.3M / $15.2M
FY2021-FY2025
Trend
+14.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 5 consecutive years, from $3M in FY2011 to $15M in FY2025.
Based on SEC 10-K filings.
$15M in FY2025 with a 3-year CAGR of +23.5%.
Increased from $12M to $15M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +23.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Actinium Pharmaceuticals, Inc.'s sg&a expense has grown for 5 consecutive years.
- 3-year CAGR of +23.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 14.1% year-over-year.
- Lowest sg&a expense in the period was in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.2M | +14.1% |
| FY2024 | $13.3M | +11.1% |
| FY2023 | $12.0M | +48.6% |
| FY2022 | $8.1M | +28.0% |
| FY2021 | $6.3M | +113.2% |
| FY2011 | $3.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026